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OBJECTIVE: Clinical trials are often the best source of efﬁ-
cacy data for economic evaluations of medical interventions.
However, their reliability can be compromised when patients
cross-over from control to experimental treatment. In two trials
evaluating lenalidomide (Len) plus high-dose dexamethasone
(Dex) vs Dex alone (MM-009/010) in patients with multiple
myeloma (MM), 47% of patients in the Dex alone group were
switched to Len +/- Dex at disease progression or following
study unblinding. Given the signiﬁcant efﬁcacy beneﬁts of
Len + Dex over Dex alone, the trial data will overestimate the
survival with Dex alone biasing the results. METHODS: Exter-
nal data from the UK Medical Research Council (MRC) MM-IV,
V, VI, and VIII trials enrolled between 1980 and 1997 were used
to derive an equation reﬂecting survival without lenalidomide,
including prognostic variables to enable adjustment for differ-
ences between the MRC and MM-009/010 trials. Applying the
MRC equation to the MM-009/010 Dex patient characteristics
yielded expected median survival time without cross-over to
Len +/- Dex. This was used to calibrate the economic model for
the Dex alone group by correcting the scale parameter of the
underlying Weibull survival equation, estimated from MM-009/
010, assuming the shape parameter remained the same.
RESULTS: Of 873 MRC patients, 826 died. Exponential survival
ﬁt the data, with age, MM performance status, M-protein level,
B2M level and time to progression as predictors. Applied to
MM-009/010 Dex patient characteristics, this yielded a median
survival of 14.9 months (95%CI: 12.3–18.0) (compared to 31
months (95%CI: 25.7–35.1) observed with cross-over in
MM-009/010). Incorporating the corrected survival function
into the economic model resulted in an estimated incremental
2.8 life-years and 1.9 QALYs gained per patient treated with
Len + Dex vs Dex alone. CONCLUSION: Using external data to
adjust estimation equations can mitigate the impact on economic
evaluations resulting from cross-over or other distorting factors
in clinical trials.
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OBJECTIVE: To describe patient characteristics, doses taken,
reason for exposure, time of exposure, treatment and severity of
poisoning in adults with acetaminophen-related exposures
reported to a regional poison control center (RPCC).
METHODS: A retrospective review was conducted of all
acetaminophen exposures that occurred between October 31,
2000 and October 31, 2003 in adults over 18 years of age who
were managed by a RPCC. Data collected included patient demo-
graphics, amount ingested, severity of exposure, time since expo-
sure, treatment, reason for exposures, exposure site, and caller
site. RESULTS: There were 175 exposures to acetaminophen;
72% were females and 28% were males in the study population.
There was no signiﬁcant difference between the mean age of
females (31.2  14.0) and males (30.9 12.3) in years. The
mean dose of acetaminophen taken was 18.7  20.4 grams and
no signiﬁcant difference in the amount ingested between males
and females. The majority of the callers seeking information on
acetaminophen ingestion were health care professionals (68%).
The mean time between the exposure and the call made to the
RPCC was 11.27  18.54 hours. Fifty percent of the patients
received acetylcysteine therapy, 27.4% received decontamination
(e.g., activated charcoal), and 22.3% received other interventions
for the treatment of acetaminophen poisoning. Females (72.4%)
were more likely (p < 0.001) to take intentional overdoses than
males (27.6%). The most common acetaminophen exposure site
was patient’s own residence (96%). The majority of the expo-
sures were acute (86.9%) rather than chronic poisoning. CON-
CLUSION: The main reason for acetaminophen exposure was
intentional and females were more likely to ingest intentionally
than males. Contacting the RPCC for advice generally occurred
beyond the time for optimal acetylcysteine effectiveness. The
majority of the exposures were due to acute poisoning.
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OBJECTIVE: To determine the economic impact of increased
prevalence of cardiometabolic risk (CMR) factors including high
blood pressure (BP), loss of glycemic control (DB), high triglyc-
erides (TG) and decreased high density lipoproteins (HDL) in
commercially insured overweight patients [Body Mass Index
(BMI) > 27 kg/m2] compared to normal weight (18  BMI <
27 kg/m2). METHODS: Patients 18–65 years old were identiﬁed
from an electronic medical record database (EMR) with CMR
factors designated by prescription orders or ICD-9 codes and
grouped into normal or overweight categories. Similar patients
with CMR factors were identiﬁed in Medstat MarketScan®
administrative claims database. Using a multivariate two-part
regression model, costs from this database were estimated for
CMR factors. Probabilities of being normal or overweight from
the EMR database were applied to the estimated costs to obtain
per patient total annual medical costs for CMR factors stratiﬁed
by normal and overweight groups. RESULTS: A total of 75,578
patients with CMR factors were identiﬁed in the EMR. Normal
[18,213 (24%)] versus overweight patients [57,365 (76%)] were
distributed as follows: BP, 29% vs. 71%; DB, 19% vs. 81%; TG,
25% vs. 75%; HDL, 37% vs. 63%; any 2 CMR factors, 13% vs.
87%; any 3 CMR factors, 9% vs. 91%; and all 4 CMR factors,
6% vs. 94%. Estimated costs from the claims database were:
high BP, $1630; DB, $1748; high TG’s, $638; low HDL, $1474;
and $2606, $2801, $3191 for 2, 3, and 4 CMR factors, respec-
tively. Applying the probability of normal or overweight and the
estimated costs to the distribution of CMR factors resulted in an
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increased projected annual cost of $998 per overweight person
with CMR factors. CONCLUSION: CMR factors are more
prevalent and lead to signiﬁcantly greater costs in an overweight
population. Weight loss interventions of overweight patients may
potentially decrease CMR factors and their associated costs.
PSY13
THE HEALTH CARE COST EFFECTS OF DIABETES AMONG
OBESE AND MORBIDLY OBESE ADULTS INTHE UNITED
STATES
Cawley J1, Rizzo JA2, Haas K3
1Cornell University, Ithaca, NY, USA, 2Stony Brook University, Stony
Brook, NY, USA, 3Ethicon Endo-Surgery, Cincinnati, OH, USA
OBJECTIVE: To determine the extent to which diabetes among
obese and morbidly obese subjects affects health care costs, and
to determine whether obesity and morbid obesity remain pre-
dictors of health care costs after controlling for diabetes.
METHODS: Data from the Medical Expenditure Panel Survey
(MEPS) for 2000–2004 are examined. Multivariate models are
estimated to predict the probability of incurring any health care
costs and health care costs incurred. These models include
obesity and morbid obesity, diabetes, age, education, occupation
category and race. Models are estimated separately by gender.
Estimates of out-of-pocket, insurer, and total costs are obtained.
Both per capita and national aggregate cost estimates are
obtained. RESULTS: Both out-of-pocket costs rise dramatically
among obese and morbidly obese subjects who are diabetic.
Relative to healthy weight individuals, out-of-pocket costs for
obese diabetics increase by $1002 per annum for females and
$1051 for males. The cost increases are even greater among
morbidly obese diabetics—$1551 for females and $1555 for
males. Insurer costs increase for obese diabetics are $3897 for
females and $3651 for males. Among morbidly obese diabetics,
these cost increases total $7302 for females and $8008 for males.
The aggregate out-of-pocket costs of obesity total $9.7 billion, of
which $8.2 billion, or 85%, are incurred by obese or morbidly
obese diabetics. Aggregate costs to insurers total $56.3 billion, of
which $32.2 billion, or 57%, are due to obese or morbidly obese
diabetics. CONCLUSION: Obese and morbidly obese diabetics
account for a disproportionate share of health care costs among
the obese population as a whole. Efforts to prevent diabetes in
this population and to reduce diabetes among obese and mor-
bidly obese individuals will lead to very substantial cost savings
to insurers and consumers.
PSY14
ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR
MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO
HAVE RECEIVED ONE PRIORTHERAPY
Deniz B1, Ishak KJ2, Shearer A3, Dale P4, Caro JJ1
1United BioSource Corporation, Concord, MA, USA, 2United
BioSource Corporation, Montreal, QC, Canada, 3Celgene
Corporation,Windsor, UK, 4United Biosource, London, England, UK
OBJECTIVE: Lenalidomide in combination with high-dose dex-
amethasone (Len + Dex), yields improved time to progression
(TTP) and survival compared to high-dose dexamethasone alone
(Dex). This study aimed to estimate long-term health and cost
consequences of Len + Dex versus Dex in Scottish patients with
multiple myeloma (MM) who have received one prior therapy.
METHODS: A discrete event simulation of a patient’s course
following initiation of Len + Dex or Dex was developed. The
model uses patient’s response (complete, partial, stable disease or
progressive disease) and estimates corresponding TTP and sub-
sequent survival based on Weibull functions derived from pooled
data from two Phase III randomized clinical trials and long-term
outcomes of UK Medical Research Council MM trials. Adverse
events and disease management costs are included. Utility by
response level was obtained from literature. Patients remain on
treatment until relapse. Disease management costs reﬂect clinical
practice in Scotland. Costs and health outcomes are discounted
at 3.5% per annum. In the base case, events and costs are
considered over two years reﬂecting trial follow-up (survival is
modeled until death). 1000 patients are simulated per analysis.
Univariate sensitivity analyses are performed around key model
parameters. RESULTS: The modeled median TTP is conservative
with Len + Dex at 13.5 months compared with 4.7 months with
Dex. This translates to QALY gains: 3.19 vs 1.39. Totals costs
with Len + Dex were £56,155 compared to £3819 with Dex,
leading to an incremental cost-effectiveness ratio of £28,980 per
QALY. Sensitivity analyses showed that outcomes remain consis-
tent through broad changes in key parameters. CONCLUSION:
Lenalidomide delivers signiﬁcant improvements in quality-
adjusted survival in a life-limiting orphan disease and yields an
estimated incremental cost per QALY which falls within a cost-
effective range.
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OBJECTIVE: To evaluate the cost-effectiveness of Erythropoie-
sis Stimulating Agent (ESA) therapy by hemoglobin (Hb)
targets (Hb < 10, 10–11, 11–12, 12–13, and >13 g/dL) in
Chronic Kidney Disease (CKD) considering the complication of
cardiovascular diseases (CVD). METHODS: Two lifetime deci-
sion analyses models for hemodialysis and pre-dialysis patients
using backward induction method were developed using
parameter values from published literatures and 2006 United
States Renal Data System. Direct costs (anemia medication
(erythopoietin or darbepoetin), hemodialysis and CVD treat-
ment) and indirect costs (patient and caregiver time cost) were
measured in 2006 US Dollars. Effectiveness was measured as
quality-adjusted life years (QALYs). All costs and QALYs were
discounted at 3% and cost-effectiveness was measured as incre-
mental cost per QALYs gained (ICER). Uncertainty was evalu-
ated using one way sensitivity analyses and threshold analyses.
RESULTS: For hemodialysis patients who initiated treatment at
age 45, higher hemoglobin targets yielded favorable ICERs
($20,050, $90,387, $67,199 and $11,216 for Hb 10–11 com-
pared to Hb < 10, Hb 11–12 compared to Hb 10–11, Hb
12–13 compared to Hb 11–12, and Hb > 13 compared to Hb
12–13, respectively). For pre-dialysis patients, Hb 11–12 and
Hb 12–13 were dominant strategies compared to Hb 10–11
and Hb 11–12, and ICER for Hb 12–13 compared to Hb > 13
was $2404. The results were more favorable for older patients
and darbepoetin treatment. Results were robust to sensitivity
analyses in pre-dialysis model, but sensitive to the CVD prob-
abilities and erythropoietin costs in hemodialysis model. CON-
CLUSION: Anemia treatment with ESA therapy was cost
effective even in Hb > 13 for hemodialysis patients using a
threshold of ICER $120,000 compared to Hb 12–13. For pre-
dialysis patients, treatment to Hb 12–13 was the most cost
effective. These results showed that higher treatment targets
compared to current national guidelines (maintaining Hb
11–12, not exceeding 13) are associated with favorable cost-
effectiveness ratios. This is consistent with Medicare’s revised
payment policies for ESA treatment.
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